1. Executive Summary
1.1 Next-Generation Antibodies: Market Overview
1.2 Contents of this Report
1.3 Research and Analysis Methods
2. Antibody Therapeutics: Scientific and Clinical Overview, 2011
2.1 Antibodies and the Immune System
2.2 How Antibodies Work
2.3 Structure of Antibodies
2.3.1 The Fab Region
2.3.2 The Fc Region
2.4 Brief History of Antibody Discovery and Innovation
2.5 Types of Therapeutic Antibody
2.5.1 Polyclonal Antibodies
2.5.2 Monoclonal Antibodies
2.5.3 Murine Monoclonal Antibodies
2.5.4 Chimeric and Humanised Monoclonal Antibodies
2.5.5 Fully Human Monoclonal Antibodies
2.5.6 Fab Fragments
2.5.7 Fusion Proteins
2.6 Currently-Approved Monoclonal Antibody Therapies
2.7 Potential Next-Generation Antibody Therapeutics
3. Antibody Therapeutics: Pipeline and Market Overview, 2011-2021
3.1 Antibody Therapeutics: Market Forecast, 2011-2021
3.1.1 Next-Generation Products will Increase Their Market Share
3.2 Antibody Therapeutics Market, 2011-2021: Pipeline Overview
3.3 Leading Players in the Antibody Field, 2011-2021
3.4 Leading National Antibody Markets
3.5 Next-Generation Therapeutic Antibody Technologies: SWOT Analysis
3.5.1 Strengths
3.5.2 Weaknesses
3.5.3 Opportunities
3.5.4 Threats
4. Engineered Antibodies Market, 2011-2021
4.1 Engineered Antibodies: Market Forecast, 2011-2021
4.2 Engineered Antibodies: Overview of the Field in 2011
4.2.1 The Major Fc Engineering Platforms
4.2.2 New Expression Systems, Purification Systems, and Other Production Improvements
4.3 Engineered Antibodies: Products and Pipeline, 2011
4.3.1 Afutuzumab and Other GlycoMAB-Engineered Products (Roche)
4.3.2 KW0761 and Other Potelligent Products (Kyowa Hakko Kirin)
4.3.3 XmAb (Xencor)
4.3.4 MGAH22 and MGA271 (Macrogenics)
4.3.5 AME-133v (Mentrik Biotech)
4.3.6 LFB-R603 (LFB)
4.4 Engineered Antibodies: SWOT Analysis
4.4.1 Strengths
4.4.2 Weaknesses
4.4.3 Opportunities
4.4.4 Threats
5. Antibody-Drug Conjugates Market 2011-2021
5.1 Antibody-Drug Conjugates: Market Forecast, 2011-2021
5.2 Antibody-Drug Conjugates: Overview of the Field in 2011
5.2.1 Existing Antibody-Drug Conjugate Products
5.3 Antibody-Drug Conjugates Pipeline, 2011
5.3.1 Trastuzumab DM-1(Roche)
5.3.2 Roche's Other ADC Collaborations (Roche/ Seattle Genetics)
5.3.3 CMC-544 (Pfizer)
5.3.4 IMGN901 (ImmunoGen)
5.3.5 BT-062 (Biotest)
5.3.6 CDX-011 and CDX-014 (Celldex)
5.3.7 BIIB015 (Biogen Idec)
5.3.8 SAR3419 and SAR566658 (Sanofi)
5.3.9 hLL1-Dox and Others (Immunomedics)
5.3.10 MDX-1203 (Bristol-Myers Squibb)
5.3.11 SGN-75 (Seattle Genetics)
5.3.12 AGS-5ME and Others (Astellas/ Agensys/ Seattle Genetics)
5.3.13 BAY 79-4620 and BAY 94-9343 (Bayer Schering/ Seattle Genetics / ImmunoGen)
5.3.14 PSMA ADC (Progenics Pharmaceuticals/ Seattle Genetics)
5.3.15 HuMax ADCs (Genmab/ Seattle Genetics)
5.3.16 Antibody-Radioisotope and Other Immunoconjugate Formats (Various)
5.4 Antibody-Drug Conjugates: SWOT Analysis
5.4.1 Strengths
5.4.2 Weaknesses
5.4.3 Opportunities
5.4.4 Threats
6. Bispecific Antibodies Market 2011-2021
6.1 Bispecific Antibodies: Market Forecast, 2011-2021
6.2 Bispecific Antibodies: Overview of the Field in 2011
6.3 Bispecific Antibodies: Pipeline, 2011
6.3.1 Blinatumumab (Micromet)
6.3.2 Other BiTE Products in Development
6.3.3 Rexomun and FBT A05 (Fresenius)
6.3.4 MM-111 (Merrimack)
6.3.5 ImmTAC System (Immunocore)
6.3.6 Tandab (Affimed)
6.3.7 DART Platform (MacroGenics)
6.3.8 CrossMAbs, LUZ-Y and Two-in-One Antibodies (Roche)
6.3.9 Electrostatic Matching (Amgen)
6.3.10 Duobodies (Genmab)
6.3.11 SEED Bodies (Merck Serono)
6.3.12 CovX-Bodies (Pfizer)
6.3.13 TCR-Like Antibodies (ReceptorLogic)
6.3.14 COMBODY (Epigen Biotech)
6.3.15 DVD-Ig (Abbott)
6.3.16 IgG-Like Bispecific (Eli Lilly)
6.3.17 BsAb (Bristol-Myers Squibb)
6.3.18 Hercules (Biogen Idec)
6.3.19 Scorpion (Emergent BioSolutions)
6.3.20 Tribody (Biotecnol)
6.3.21 Dock-and-Lock (ImmunoMedics)
6.3.22 Immunocytokines (ImmunGene)
6.3.23 COBRA (Merus)
6.4 Bispecific Antibodies: SWOT Analysis
6.4.1 Strengths
6.4.2 Weaknesses
6.4.3 Opportunities
6.4.4 Threats
7. Antibody Fragments Market 2011-2021
7.1 Antibody Fragments: Market Forecast, 2011-2021
7.2 Antibody Fragments: Overview of the Field in 2011
7.3 Antibody Fragments: Pipeline, 2011
7.3.1 CEP-37247 (Cephalon)
7.3.2 GSK1827771 and Others (GlaxoSmithKline)
7.3.3 Nanobodies (Ablynx)
7.3.4 ESBA105 (ESBATech)
7.3.5 Unibodies (GenMab)
7.3.6 IgNARs (Pfizer)
7.4 Antibody Fragments: SWOT Analysis, 2011
7.4.1 Strengths
7.4.2 Weaknesses
7.4.3 Opportunities
7.4.4 Threats
8. Alternative Binding Proteins Market 2011-2021
8.1 Alternative Binding Proteins: Market Forecast, 2011-2021
8.2 Alternative Binding Proteins: Overview of the Field in 2011
8.3 Alternative Binding Proteins: Pipeline, 2011
8.3.1 Adnectins (Adnexus)
8.3.2 DARPins (Molecular Partners)
8.3.3 Anticalins (Pieris)
8.3.4 Affibodies (Affibody)
8.3.5 Avimers (Amgen)
8.3.6 Transbodies (Pfizer)
8.3.7 Fynomers (Covagen)
8.3.8 Affilins (Scil Proteins)
8.3.9 Evibodies (Arana Therapeutics)
8.3.10 C-Type Lectins (Borean Pharma)
8.4 Alternative Binding Proteins: SWOT Analysis, 2011
8.4.1 Strengths
8.4.2 Weaknesses
8.4.3 Opportunities
8.4.4 Threats
9. Polyclonal Antibodies Market 2011-2021
9.1 Polyclonal Antibodies: Market Forecast, 2011-2021
9.2 Polyclonal Antibodies: Overview of the Field in 2011
9.3 Polyclonal Antibodies: Pipeline, 2011
9.3.1 Symphogen Polyclonal Antibodies Platform
9.3.2 Merus HYDRA Polyclonal Antibodies Platform
9.4 Polyclonal Antibodies: SWOT Analysis, 2011
9.4.1 Strengths
9.4.2 Weaknesses
9.4.3 Opportunities
9.4.4 Threats
10. Biosimilar Antibodies Market 2011-2021
10.1 Biosimilar Antibodies: Market Forecast, 2011-2021
10.2 Overview of Biosimilar Antibodies
10.3 Biosimilar Antibodies: Prospects in 2011
10.3.1 Biosimilar Antibody Regulatory Guidance in Europe
10.4 Biosimilar Antibodies: SWOT Analysis, 2011
10.4.1 Strengths
10.4.2 Weaknesses
10.4.3 Opportunities
10.4.4 Threats
11. Research Interviews
11.1 Interview with Dr Jason Kantor
11.1.1 On Progress in Antibody-Drug Conjugates
11.1.2 On Pharma Strategies for Next-Generation Antibody Technologies
11.1.3 On Competition between Next-Generation Sectors
11.1.4 On Engineered Antibodies
11.1.5 On Biosimilars
11.1.6 On Next-Generation Antibodies and Personalised Medicine
11.2 Interview with Professor Arne Skerra
11.2.1 On the Benefits of Non-Immunoglobulin Binding Proteins
11.2.2 On the Alternative Binding Proteins Pipeline
11.2.3 On Big Pharma Buyouts and Business Drivers in the Sector
11.2.4 On Antibody Fragments Compared to Alternative Binding Proteins
11.2.5 On Pieris' Lipocalin Scaffolds and Lead Candidate Angiocal
11.2.6 On Immunogenicity and Plasma Half-Life
12. Conclusions
12.1 A New Generation of Antibody Products is Emerging
12.2 Some Next-Generation Antibodies are Already Here
12.3 Other Innovative Platforms are about to Achieve Market Breakthrough
12.4 Next-Generation Products Will Have Important Consequences for Other Antibodies
List of Tables
Table 2.1 Timeline of Salient Innovations and Market Launches in the Therapeutic Antibodies Field
Table 2.2 Types of Therapeutic Monoclonal Antibody Product, 2011
Table 2.3 Murine Antibody Products on the Market, 2011
Table 2.4 Chimeric Antibody Products on the Market, 2011
Table 2.5 Humanised Antibody Products on the Market, 2011
Table 2.6 Fully-Human Antibody Products on the Market, 2011
Table 2.7 Fab Fragment Antibody Products on the Market, 2011
Table 2.8 Fusion Protein Products on the Market, 2011
Table 2.9 Monoclonal Antibodies Approved in the US, 2011
Table 2.10 Monoclonal Antibodies Approved Outside US Only
Table 2.11 Different Categories of Next-Generation Antibodies Considered in this Report
Table 2.12 Next-Generation Products Already on the Market, 2011
Table 3.1 Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2010
Table 3.2 Next-Generation Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2010
Table 3.3 Therapeutic Antibodies Market: Revenues ($bn), AGR (%), CAGR (%), 2010-2015
Table 3.4 Therapeutic Antibodies Market: Revenues ($bn), AGR (%), CAGR (%), 2016-2021
Table 3.5 Next-Generation Therapeutic Antibodies Market: Revenues ($m), AGR (%), CAGR (%), 2010-2015
Table 3.6 Next-Generation Therapeutic Antibodies Market: Revenues ($m), AGR (%), CAGR (%), 2016-2021
Table 3.7 Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2015
Table 3.8 Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2021
Table 3.9 Next-Generation Antibodies Market, Breakdown by Categories: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibodies Market (%), Shares of Overall Antibodies Market (%), 2010-2015
Table 3.10 Next-Generation Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2015
Table 3.11 Next-Generation Antibodies Market, Breakdown by Categories: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibodies Market (%), Shares of Overall Antibodies Market (%), 2016-2021
Table 3.12 Next-Generation Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2021
Table 3.13 Next-Generation Antibody Therapeutics: Leading Pipeline Contenders, 2011
Table 3.14 Top 10 Next-Generation Antibody Therapeutic Technology Platforms, 2011
Table 3.15 Antibodies Market, Breakdown by National Market: Revenues ($bn), Market Shares (%), 2010
Table 3.16 Strengths and Weaknesses of the Next-Generation Antibodies Sector, 2011
Table 3.17 Opportunities and Threats in the Next-Generation Antibodies Sector, 2011
Table 4.1 Engineered Antibodies Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2010-2015
Table 4.2 Engineered Antibodies Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2016-2021
Table 4.3 Engineered Antibodies Market: Clinical Pipeline, 2011
Table 4.4 Engineered Antibodies Market: Preclinical Pipeline, 2011
Table 4.5 Engineered Antibody Products Based on GlycArt Technology, 2011
Table 4.6 Engineered Antibody Products Based on POTelligent Technology, 2011
Table 4.7 Engineered Antibody Products Based on XmAb Technology, 2011
Table 4.8 Strengths and Weaknesses of the Engineered Antibodies Sector, 2011
Table 5.1 Antibody-Drug Conjugates Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2010-2015
Table 5.2 Antibody-Drug Conjugates Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2016-2021
Table 5.3 Antibody-Drug Conjugates Market: Clinical Pipeline, 2011
Table 5.4 Antibody-Drug Conjugates Market: Preclinical Pipeline, 2011
Table 5.5 Immunogen ADC Collaborations, 2011
Table 5.6 Seattle Genetics ADC Collaborations, 2011
Table 5.7 Antibody-Radioisotope and Other Immunconjugate Formats: Clinical Pipeline, 2011
Table 5.8 Strengths and Weaknesses of the Antibody-Drug Conjugates Sector, 2011
Table 5.9 Opportunities and Threats in the Antibody-Drug Conjugates Sector, 2011
Table 6.1 Bispecific Antibodies Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2010-2015
Table 6.2 Bispecific Antibodies Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2016-2021
Table 6.3 Bispecific Antibodies Market: Clinical Pipeline, 2011
Table 6.4 Bispecific Antibodies Market: Preclinical Pipeline, 2011
Table 6.5 Strengths and Weaknesses of the Bispecific Antibodies Sector, 2011
Table 6.6 Opportunities and Threats in the Bispecific Antibodies Sector, 2011
Table 7.1 Antibody Fragments Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2010-2015
Table 7.2 Antibody Fragments Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2016-2021
Table 7.3 Antibody Fragments: Clinical Pipeline, 2011
Table 7.4 Antibody Fragments: Preclinical Pipeline, 2011
Table 7.5 Strengths and Weaknesses of the Antibody Fragments Sector, 2011
Table 7.6 Opportunities and Threats in the Antibody Fragments Sector, 2011
Table 8.1 Alternative Binding Proteins Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2016-2021
Table 8.2 Alternative Binding Proteins: Clinical Pipeline, 2011
Table 8.3 Alternative Binding Proteins: Preclinical Pipeline, 2011
Table 8.4 Strengths and Weaknesses of the Alternative Binding Proteins Sector, 2011
Table 8.5 Opportunities and Threats in the Alternative Binding Proteins Sector, 2011
Table 9.1 Polyclonal Antibodies Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2010-2015
Table 9.2 Polyclonal Antibodies Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2016-2021
Table 9.3 Polyclonal Antibodies: Clinical Pipeline, 2011
Table 9.4 Polyclonal Antibodies: Preclinical Pipeline, 2011
Table 9.5 Strengths and Weaknesses of the Polyclonal Antibodies Sector, 2011
Table 9.6 Opportunities and Threats in the Polyclonal Antibodies Sector, 2011
Table 10.1 Biosimilar Antibodies Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2010-2015
Table 10.2 Biosimilar Antibodies Market: Revenues ($m), AGR (%), CAGR (%), Share of Next-Generation Antibodies Market (%), Share of Overall Antibodies Market (%), 2016-2021
Table 10.3 Strengths and Weaknesses of the Biosimilar Antibodies Sector, 2011
Table 10.4 Opportunities and Threats for the Biosimilar Antibodies Sector, 2011
List of Figures
Figure 3.1 Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2010
Figure 3.2 Next-Generation Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2010
Figure 3.3 Therapeutic Antibodies Market: Revenues ($bn), 2010-2015
Figure 3.4 Therapeutic Antibodies Market: Revenues ($bn), 2016-2021
Figure 3.5 Next-Generation Therapeutic Antibodies Market: Revenues ($m), 2010-2015
Figure 3.6 Next-Generation Therapeutic Antibodies Market: Revenues ($m), 2016-2021
Figure 3.7 Antibodies Market Breakdown, Revenues ($m), Market Shares (%), 2015
Figure 3.8 Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2021
Figure 3.9 Next-Generation Antibodies Market, Breakdown by Categories: Revenues ($m), 2010-2015
Figure 3.10 Next-Generation Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2015
Figure 3.11 Next-Generation Antibodies Market, Breakdown by Categories: Revenues ($m), 2016-2021
Figure 3.12 Next-Generation Antibodies Market Breakdown: Revenues ($m), Market Shares (%), 2021
Figure 3.13 Antibodies Market, Breakdown by National Market: Revenues ($bn), Market Shares (%), 2010
Figure 4.1 Engineered Antibodies Market: Revenues ($m), 2010-2015
Figure 4.2 Engineered Antibodies Market: Revenues ($m), 2016-2021
Figure 5.1 Antibody-Drug Conjugates Market: Revenues ($m), 2010-2015
Figure 5.2 Antibody-Drug Conjugates Market: Revenues ($m), 2016-2021
Figure 6.1 Bispecific Antibodies Market: Revenues ($m), 2010-2015
Figure 6.2 Bispecific Antibodies Market: Revenues ($m), 2016-2021
Figure 7.1 Antibody Fragments Market: Revenues ($m), 2015-2021
Figure 8.1 Alternative Binding Proteins Market: Revenues ($m), 2016-2021
Figure 9.1 Polyclonal Antibodies Market: Revenues ($m), 2015-2021
Figure 10.1 Biosimilar Antibodies Market: Revenues ($m), 2010-2015
Figure 10.2 Biosimilar Antibodies Market: Revenues ($m), 2016-2021
Companies Listed
Abbott Laboratories
Ablynx
Alexion Pharmaceuticals
Amgen
Arana Therapeutics
Astellas Pharma
AstraZeneca
Affibody
Affimed Therapeutics
American Society of Clinical Oncology
Applied Molecular Evolution
Bayer Healthcare
Bayer Schering
BayTech Venture Capital
BioCon
Biogen Idec
Biolex Therapeutics
BioTech Pharma
Biotecnol
Biotest Pharmaceuticals
BioWa
Boehringer Ingelheim
Borean Pharma
Bradmer Pharmaceuticals
Bristol-Myers Squibb
Cancer Research Technology
Celldex Therapeutics
Celltech
Cell Therapeutics
Cephalon
Cevec Pharmaceuticals
Chengdu Hoist Biotech
Corixa Corporation
Crucell
Covagen
Daiichi Sankyo
Delenex Therapeutics
Diversys
Domantis
Dresden University of Technology
Dr. Reddy's Laboratories
Elan Pharmaceuticals
Eli Lilly
Emergent BioSolutions
Epigen Biotech
ESBATech
EuroFarma
European Medicines Agency (EMEA/EMA)
Food and Drug Administration (US FDA)
Forbion Capital
Fresenius
Genentech
Genmab
Gilde Healthcare Partners
GlaxoSmithKline (GSK)
Global Life Science Ventures
GlycArt
GTV Biotherapeutics
Haptogen
Human Genome Sciences
ImmunGene
Immunocore
ImmunoGen
Immunomedics
Isu Abxis
Johnson & Johnson
Kyowa Hakko Kirin
Laboratoires Français de Fractionnement et des Biotechnologies (LFB)
Ludwig Institute for Cancer Research
Mabgene
Macrogenics
Medarex
MedImmune
Meiji Seika Pharma
Memorial Sloan-Kettering Cancer Center
Mentrik Biotech
Merck & Co.
Merck KGaA
Merck Serono
Merrimack Pharmaceuticals
Merus Biopharmaceuticals
Micromet
Molecular Partners
MorphoSys
Novartis
OrbiMed Advisors
Oslo University Hospital
Oxford BioMedica
Peptech Corporation
Percivia
Pfizer
Pharming Healthcare
Pieris
Progenics Pharmaceuticals
RBC Capital Markets
ReceptorLogic
Regeneron Pharmaceuticals
Roche
Roslin Institute
Sanofi
Scil Proteins
SeaGen Secure
Seattle Genetics
Soroka University Medical Centre
Spectrum Pharmaceuticals
Sutro Biopharma
Swiss Federal Institute of Technology
Symphogen
Takeda Pharmaceutical Company
Technical University of Munich
Teva Pharmaceutical Industries
Tufts Centre for Drug Discovery
UCB
University of Aberdeen
University of Oxford
Viragen
Wacker Biosolutions
Wyeth
Xencor
